National Bank of Canada’s Axsome Therapeutics AXSM Stock Holding History

National Bank of Canada’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.25K	Buy	+37	New	+$6.39K	﹤0.01%	2425
2025 Q1	–	Sell	-31	Closed	-$2.62K	–	2853
2024 Q4	$2.62K	Buy	+31	New	+$2.85K	﹤0.01%	2548
2024 Q3	–	Sell	-610	Closed	-$49.4K	–	2766
2024 Q2	$49.4K	Hold	610	–	–	﹤0.01%	1690
2024 Q1	$44.2K	Buy	610 +10	+2%	+$839	﹤0.01%	1799
2023 Q4	$46.2K	Sell	600 -59,603	-99%	-$3.98M	﹤0.01%	1791
2023 Q3	$4.02M	Sell	60,203 -9,220	-13%	-$689K	0.01%	861
2023 Q2	$4.99M	Buy	+69,423	New	+$5.12M	0.01%	716

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

National Bank of Canada's AXSM Position: Q1 2026 in Review

National Bank of Canada opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 37 shares worth $6.25K. The stake represents ﹤0.01% of the portfolio and ranks #2425 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in AXSM as recently as Q4 2024.

National Bank of Canada first reported a position in AXSM in Q2 2023 and has held it in 7 quarters since. The position peaked at $4.99M in Q2 2023. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

National Bank of Canada held 37 shares of Axsome Therapeutics worth $6.25K as of Q1 2026.
Axsome Therapeutics was a new National Bank of Canada position in Q1 2026.
Axsome Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2425 holding.
National Bank of Canada first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 7 quarters since.
National Bank of Canada's Axsome Therapeutics position peaked at $4.99M in Q2 2023.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.